Foley Hoag LLP advised Ginkgo Bioworks on the deal.
Ginkgo Bioworks, Inc., the organism company, closed a collaboration and license agreement with Biogen (Nasdaq: BIIB) to develop a next-generation recombinant adeno-associated virus (AAV) production platform. Using its synthetic biology expertise, Ginkgo seeks to improve the efficiency of AAV-producing plasmid vectors and cell lines, which could accelerate Biogen’s development of novel gene therapies.
Ginkgo is building a platform to make programming cells as easy as programming computers. The company’s platform is enabling the growth of biotechnology across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo is also actively supporting a number of COVID-19 response efforts, including community testing, epidemiological tracing, vaccine development and therapeutics discovery.
Foley Hoag attorneys Sarah Cooleybeck (Picture), Kathryn Lumb and Mark Potash represented Ginkgo in the transaction, with assistance from Nicola Lemay and Alison Bauer.
Law Firms: Foley Hoag LLP;
Clients: Ginkgo Bioworks Inc;